1.32  0.01 (0.76%)		05-08 16:00
Open: 1.3 High: 1.35 Volume: 300,729		Pre. Close: 1.31 Low: 1.26 Market Cap: 51(M)

Short term
Mid term
Targets	6-month :	1.72	1-year :	2.01
Resists	First :	1.48	Second :	1.72
Pivot price	1.32
Supports	First :	1.28	Second :	1.15
MAs	MA(5) :	1.35	MA(20) :	1.33
	MA(100) :	1.64	MA(250) :	1.58
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	47.1	D(3) :	54.7
RSI	RSI(14): 46.4
52-week	High :	3.19	Low :	0.87

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ MAIA ] has closed above bottom band by 48.7%. Bollinger Bands are 72% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.35 - 1.36	1.36 - 1.37
Low:	1.24 - 1.25	1.25 - 1.26
Close:	1.31 - 1.32	1.32 - 1.33

MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer, primarily non-small cell lung cancer. Its lead asset, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded in 2018 and is headquartered in Chicago, Illinois.

Thu, 16 Apr 2026
MAIA Biotechnology Activates First U.S. Site for Ongoing - GlobeNewswire

Thu, 16 Apr 2026
MAIA Biotechnology opens first U.S. site for lung cancer trial - Investing.com

Thu, 16 Apr 2026
$2.3M NIH-backed lung cancer study opens first U.S. site - Stock Titan

Tue, 14 Apr 2026
MAIA Biotechnology (MAIA) CEO awarded 800,000 stock options at $1.28 - Stock Titan

Tue, 14 Apr 2026
MAIA Biotechnology (MAIA) grants 30,000 stock options to finance head - Stock Titan

Wed, 08 Apr 2026
MAIA (NYSE: MAIA) uses $33M raise to fund Phase 3 lung cancer study - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.